Tag Archives: antibiotics

BIO CEO Company Snapshot: Tetraphase Pharmaceuticals

tetraphase

The BIO CEO & Investor Conference is now just a week away, and buzz for the event has never been greater. Tomorrow, Inside BIO is hosting its first ever twitter chat to discuss the annual buyside survey, which has been getting great responses from the investor community. Presentation spots are still sold out as well, and we’re continuing to highlight those companies slated to present. One such company is Tetraphase Pharmaceuticals, who went public this Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

New CDC Report on Alarming Rates of Antibiotic-Resistant Infections

MRSA

Every year in the United States, 2 million people acquire an antibiotic-resistant infection. Of those, at least 23,000 die as a result. That’s according to an alarming report  released last week by the CDC. Antibiotic resistance is one of the largest threats to global health. The prevalence of antibiotic-resistant infections is not only a serious world-wide public health issue, it also adds considerable costs to the U.S. healthcare system. According to the CDC: Studies have estimated Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

#BIF2012 Company Snapshot: ContraFect Corporation

ContraFect

The BIO Investor Forum is fast approaching! Below you’ll find our first Company Snapshot of one of the event’s presenting companies, ContraFect Corporation. Continue reading to learn more about ContraFect’s product, their strategies, and what you can expect from their company in the coming months. Company Snapshot What is your company’s lead product or technology? ContraFect is a private company developing biotherapeutics for resistant, life threatening infections. Our lead compound, CF-301, is a bacteriophage lysin, Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , ,

Resistance is Futile – SuperDrugs for SuperBugs

800px-Acinetobacter_baumannii

“MRSA’s kill 100,000 people a year, more than AIDS,” said Mark Leuchetenberger, President and CEO, Rib-X Pharmaceuticals, Inc. With new superbugs on the rise and new superdrugs continuing to decline, the antibacterial drug discovery market is anyone’s for the taking. Attendees of the 10th Annual BIO Investor Forum participating in the Infectious Disease Therapeutic Workshop heard from an engaging panel that seemed to agree the economics of this category are driven by two things: society expects Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , ,

BIO submits comments on Australian Senate Patent Amendment

The Australian Senate has proposed the Patent Amendment (Human Genes and Biological Materials) Bill 2010 that aims to ban ’gene patents’.  From the BIO Submission to Australian Senate Legal Committee on Patent Amendment: This amendment would exclude from patent protection “any” biological material, whether a human gene or otherwise, that is substantially identical to a naturally-occuring biological material.  Specifically, the amendment states that the following materials would be catergorically declared unpatentable:             “biological materials including their components Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , , , , , , , , , , ,